Brege Laura 4

What Happened
Laura Brege, a director of Mirum Pharmaceuticals (MIRM), was granted two equity awards on 2026-06-15: 3,772 shares and 1,980 deferred stock units. Both grants are recorded at $0.00 (no cash paid) and are derivative awards/stock units rather than open-market purchases or sales. Total granted = 5,752 units; no immediate cash value was exchanged.

Key Details

• Transaction date: 2026-06-15 (Form filed 2026-06-17). Transaction code: A (award/grant).
• Grant prices: $0.00 for both awards; aggregate cash value at grant = $0.
• Shares owned after transaction: Not specified in this Form 4 filing.
• Footnote summary:
  • F1: The 3,772-share award vests on the first anniversary of the grant, but will be fully vested no later than the issuer’s 2027 annual stockholder meeting.
  • F2: The 1,980 deferred stock units each represent a contingent right to one share, vest on the first anniversary (or fully vest by the 2027 annual meeting), and will be paid in common stock upon the earlier of (i) a change in control or (ii) within 60 days after separation from service.
• Filing timeliness: Filed two days after the reported transaction date; no late filing flag in the record.

Context
These are non-cash director compensation awards and should be read as deferred/contingent equity rather than an outright buy or sale. Deferred stock units do not immediately increase tradable share count — they convert to shares only upon vesting and specified payout events (change in control or separation).